The latest trendy smart wearable? A glucose monitor for adults who aren’t dealing with diabetes. Here’s what @nicnguyen learned when she wore one for two weeks. https://t.co/MV4Uslj3vu ...

Group 1: Novo Nordisk - Novo Nordisk has faced clinical setbacks and unimpressive financial results, leading to significant underperformance in the market over the past 12 months, but the stock now appears attractive [4][9] - The company has strong prospects in the weight management market, with its product Wegovy continuing to grow in sales and awaiting FDA approval for an oral formulation [5][6] - Novo Nordisk is diversifying its pipeline beyond diabetes and obesity, developing treatments for conditions such as hemophilia, Parkinson's disease, and Alzheimer's disease [7] - The company's forward price-to-earnings ratio is 16.8, slightly above the healthcare industry average of 16.3, indicating reasonable valuation [8] - Novo Nordisk has increased its annual dividend per share by nearly 284% over the past decade, with a forward yield of 2.3%, which is above the S&P 500 average of 1.3% [10] Group 2: DexCom - DexCom specializes in continuous glucose monitoring (CGM) systems for diabetics, which provide constant blood sugar level measurements, distinguishing itself from traditional blood glucose meters [11] - The company experienced a slowdown in top-line growth last year due to higher-than-expected rebates in the U.S., but these are considered short-term issues that do not affect long-term prospects [12] - There is significant growth potential in the U.S. market, as many eligible patients have yet to adopt CGM technology, and globally, only a small percentage of diabetics currently use CGM [13][14] - DexCom is expected to benefit from increased insurance coverage for CGM technology, leading to consistent revenue and earnings growth [14][15]

The latest trendy smart wearable? A glucose monitor for adults who aren’t dealing with diabetes. Here’s what @nicnguyen learned when she wore one for two weeks. https://t.co/3aaHNesiUz ...

The latest trendy smart wearable? A glucose monitor for adults who aren’t dealing with diabetes. Here’s what @nicnguyen learned when she wore one for two weeks. https://t.co/Tr05X6dbuV ...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=155069&fr ...

Core Insights - Trinity Biotech has reached a critical profitability inflection point and expects to be Adjusted EBITDA positive and cash flow positive starting Q3 2025 [1][5][10] - The company has undergone significant operational restructuring to reduce costs and improve efficiency, laying the groundwork for sustainable profitability [5][10] - Trinity Biotech is focusing on growth opportunities, including the international rollout of new products and the development of innovative diagnostic solutions [5][12] Financial Performance - For Q1 2025, Trinity Biotech reported revenue of $7.6 million, with a gross profit of $1.9 million and an operating loss of $6.5 million [10] - The company anticipates a significant increase in revenue for Q2 2025, projecting a range of approximately $11 million to $12 million due to ramped-up manufacturing and normalized demand for rapid HIV tests [10] - The company expects further revenue growth in Q3 2025, driven by the resumption of manufacturing and supply of its flagship rapid HIV test, TrinScreen HIV [10] Strategic Developments - The company is advancing its next-generation continuous glucose monitoring (CGM) solution, which is seen as a major growth opportunity in the $13 billion global CGM market [5] - Trinity Biotech is also progressing towards commercialization of key medium-term growth drivers, including a preeclampsia screening test and a prostate cancer test [5] - The company has completed a pre-pivotal trial on its upgraded sensor technology for the CGM solution and plans to unveil key aspects of this innovative design soon [5]

The latest trendy smart wearable? A glucose monitor for adults who aren’t dealing with diabetes. Here’s what @nicnguyen learned when she wore one for two weeks. https://t.co/cbgnJpdMse ...

Comprehensive analysis confirms safety and strong accuracy of Glucotrack's innovative blood-based continuous glucose monitoring technology, with MARD of 7.7% RUTHERFORD, N.J. and STOCKHOLM, June 25, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced results from its completed first-in-human clinical study presented at the American Diabetes Association's (A ...

Key Takeaways Dexcom saw record new patient starts and expanded T2D access coverage in Q1 2025. Dexcom's 15-day G7 and OTC Stelo drive innovation and support long-term commercial growth. Dexcom faces margin pressure from freight costs, inflation and an ongoing FDA warning letter.DexCom (DXCM) delivered robust first-quarter 2025 results, underpinned by strong category demand, record new patient growth and meaningful progress in its long-term strategic initiatives. As the year progresses, several key growth ...

1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-60 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock par value $0.001 per share (t ...